Supplementary Table 3 contains the top DEGS from an unbiased analysis of RNAseq from MYC+ DLBCL cell lines treated with CDK9 inhibitors.</p
Enitociclib treatment results in complete regression of MYC-overexpressing SU-DHL-10 lymphoma growth...
© 2016 Dr. Gareth Peter GregoryAggressive B-cell lymphomas include diffuse large B-cell lymphoma, Bu...
BACKGROUND AND PURPOSE: The cyclin-dependent kinase CDK9 is an important therapeutic target but curr...
Supplementary Table 1 shows the enitociclib toxicity in a panel of lymphoma cell lines ranked by IC5...
Supplementary Table 6 captures the maximal downregulation timepoint for novel and known DEGs post en...
Supplementary Table 5 shows estimated pharmacodynamic parameters for MYC and MCL1 mRNA in blood foll...
Response and pharmacokinetics properties of patients with DH-DLBCL and other patients with MYC+ NHL ...
Supplementary Table 4 shows the baseline characteristics of DH-DLBCL and other MYC+ NHL Patients (n=...
Supplementary Figure 1 shows the principal component analysis of RNA sequencing of either SU-DHL-4 a...
Supplementary Table 2 contains the statistical analysis for pSer2 downregulation in SU-DHL-4 and SU-...
Supplementary Figure 2: Downregulation of MYC and MCL1 is detected in the whole blood of Enitociclib...
Enitociclib delivers robust inhibition of RNA polymerase II Ser2 phosphorylation for up to 48 hours ...
Enitociclib depletes mRNA transcripts, MYC and MCL1; downregulates Myc and Mcl-1 protein levels and ...
Enitociclib treatment confers a robust shift in transcriptional activity in MYC+ DLBCL cell lines. A...
Comparison of DEGs identified in MYC+ DLBCL cell lines to blood samples from enitociclib-treated pat...
Enitociclib treatment results in complete regression of MYC-overexpressing SU-DHL-10 lymphoma growth...
© 2016 Dr. Gareth Peter GregoryAggressive B-cell lymphomas include diffuse large B-cell lymphoma, Bu...
BACKGROUND AND PURPOSE: The cyclin-dependent kinase CDK9 is an important therapeutic target but curr...
Supplementary Table 1 shows the enitociclib toxicity in a panel of lymphoma cell lines ranked by IC5...
Supplementary Table 6 captures the maximal downregulation timepoint for novel and known DEGs post en...
Supplementary Table 5 shows estimated pharmacodynamic parameters for MYC and MCL1 mRNA in blood foll...
Response and pharmacokinetics properties of patients with DH-DLBCL and other patients with MYC+ NHL ...
Supplementary Table 4 shows the baseline characteristics of DH-DLBCL and other MYC+ NHL Patients (n=...
Supplementary Figure 1 shows the principal component analysis of RNA sequencing of either SU-DHL-4 a...
Supplementary Table 2 contains the statistical analysis for pSer2 downregulation in SU-DHL-4 and SU-...
Supplementary Figure 2: Downregulation of MYC and MCL1 is detected in the whole blood of Enitociclib...
Enitociclib delivers robust inhibition of RNA polymerase II Ser2 phosphorylation for up to 48 hours ...
Enitociclib depletes mRNA transcripts, MYC and MCL1; downregulates Myc and Mcl-1 protein levels and ...
Enitociclib treatment confers a robust shift in transcriptional activity in MYC+ DLBCL cell lines. A...
Comparison of DEGs identified in MYC+ DLBCL cell lines to blood samples from enitociclib-treated pat...
Enitociclib treatment results in complete regression of MYC-overexpressing SU-DHL-10 lymphoma growth...
© 2016 Dr. Gareth Peter GregoryAggressive B-cell lymphomas include diffuse large B-cell lymphoma, Bu...
BACKGROUND AND PURPOSE: The cyclin-dependent kinase CDK9 is an important therapeutic target but curr...